The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
File
Thomas M
TM
Northeastern Ohio Universities College of Medicine, Rootstown, OH; Infectious Disease Service, Summa Health System, Akron, OH, USA. filet@summa-health.org
D000328:Adult; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D012852:Sinusitis / Q000188:drug therapy / Q000382:microbiology
D000900:Anti-Bacterial Agents; D019980:Amoxicillin-Potassium Clavulanate Combination